Research & Education

IASLC Atlas of ALK and ROS1 Testing in Lung Cancer

September 21, 2017 at 1:00 PM EST; September 21, 2017 at 6:00 PM EST - Recording Available
   

Prof. Keith Kerr,
BSc, MB, ChB, FRCPath, FRCPE
Department of Pathology
Aberdeen University Medical School
Aberdeen Royal Infirmary
Aberdeen, UK

 Ming-Sound Tsao, MD, FRCPC

Senior Scientist
Princess Margaret Cancer Center\Professor of
Laboratory Medicine and Pathology
M. Qasim Choski Chair in Lung Cancer Translational Research
University of Toronto, Canada

 

Name of Reviewer(s): 

 Laurie Gaspar, MD Advisory Board/Honoraria from Astrazeneca.

Name of Planner(s): 

 

Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose

Name of Activity: 

 

IASLC Atlas of ALK and ROS1 Testing in Lung Cancer

Date of Activity:

 

09/21/2017

Faculty/Speaker(s)Disclosure:

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

 

Speaker: Professor Keith Kerr :For each entity I have speakers and advisory board honoraria from: AZ, BI, Eli Lilly, MSD, Merck Serono, Novartis, Pfizer, Roche.

 

 Speaker: Ming-Sound Tsao, MD: Speaker/Advisory Board, Honoraria and research grants from: AstraZeneca, Merck Canada, Bristol Myers Squibb, Pfizer, Roche/Ventana.

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

    No

If yes, please list:

These live webinars are intended to help pathologists, scientists and physicians better understand the background, protocol and interpretation of results of ALK and ROS1 testing for NSCLC patients.

Goal and Purpose:

  • Understand the use of FISH and IHC to detect ALK and ROS1 in non-small cell lung cancer.
  • Give clinicians guidance in the interpretation of test results.
  • Optimize treatment of ALK  and ROS1 Positive Lung Cancers by identifying patients most likely to benefit from ALK and ROS1 inhibitor therapy.

Following the presentation, there will be ample time for discussion and a question/answer session.  Attendees will be able to submit questions and comments to the faculty via internet chat.

Program Objectives:

  • Introduce clinicians to the reference Atlas of Alk and ROS1 testing

  • Provide clinicians and scientists with a clear understanding of the background, testing protocols and interpretation of results of ALK and RPOS1 testing.

  • Identify and review the use of FISH (Fluoroescence In Situ Hybridization) and IHC (ImmunoHistoChemistry) to detect ALK.

In order to receive CME credit, attendees must fill out a program evaluation.

DOWNLOAD KEITH KERR'S PRESENTATION 

DOWNLOAD MING-SOUND TSAO's PRESENTATION

CME INFORMATION:

 Financial Commercial and Conflicts of Interest Disclosure Form

IASLC Guidelines For Individuals Planning and/or Presenting a IASLC CME Activity

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

CME INFORMATION:

DEFINITION OF CME

Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public.

Financial/Commercial Relationships DISCLOSURES

A conflict of interest (COI) is created and exists when individuals in a position to control the content of CME (or their spouses/partners) have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership and other activities for which remuneration is received or expected. 

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME Department assures that the planners/reviewers/authors/faculty/peer reviewers et al. conflicts of interest were identified, reviewed and resolved fromall individuals involved in the development or able to influence and control the content of this CME activity. The IASLC CME Department assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from all IASLC CME activity presentations.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee and an independent reviewer. COI will be evaluated by the IASLC Board of Directors for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. The IASLC CME Department is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making the presentation, but rather to identify and resolve any conflicts of interest that may control the content of the activity. It is also intended that any potential conflict be identified openly so that the listeners have a full disclosure of the facts and may form their own judgments about the presentation. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

All other faculty/contributors have reported no commercial affiliation associated with this conference or intent to reference off-label/unapproved uses of products or devices in their presentations.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.

Attendees can now view IASLC Live webinars via their mobile device.  

Downloading of the Cisco WebEx Meetings app is required.

Once the app is installed on your device you will need to enter the event number for each session.

 Registration is required for all IASLC webinars.